Evaluation of adverse events of CDK4/6 inhibitors: a real-world study based on the FAERS database
Background and purpose: The development and approval of inhibitors of cyclin-dependent kinase 4/6 (CDK4/6) is an essential milestone in treating hormone receptor-positive metastatic breast cancer. The efficacy of these drugs is similar, but the adverse events (AE) are different, directly affecting t...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Editorial Office of China Oncology
2023-10-01
|
| Seri Bilgileri: | Zhongguo aizheng zazhi |
| Konular: | |
| Online Erişim: | http://www.china-oncology.com/fileup/1007-3639/PDF/1698723436180-1489019076.pdf |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|